NCT02934568 - Ribociclib (LEE011) Rollover Study for Continued Access | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2016

Primary Completion Date

August 31, 2026

Study Completion Date

September 1, 2026

Conditions

Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

Interventions

DRUG

LEE011

Single agent LEE011 or in combination with other treatments

Trial Locations (13)

10002

COMPLETED

Novartis Investigative Site, Taipei

13790

COMPLETED

Broome Oncology SC-2, Johnson City

28041

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Madrid

28050

COMPLETED

Novartis Investigative Site, Madrid

38105

RECRUITING

St Jude Childrens Research Hospital, Memphis

69373

COMPLETED

Novartis Investigative Site, Lyon

70403

RECRUITING

Novartis Investigative Site, Tainan City

94800

COMPLETED

Novartis Investigative Site, Villejuif

119228

COMPLETED

Novartis Investigative Site, Singapore

35294-3300

COMPLETED

University Of Alabama At Birmingham, Birmingham

02215

COMPLETED

Dana Farber Cancer Institute Main Site, Boston

48109-5930

COMPLETED

The Regents of the University of Michigan, Ann Arbor

08035

WITHDRAWN

Novartis Investigative Site, Barcelona